Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLAKelly G. Paulson(Swedish Medical Center), Aude G. Chapuis(University of Washington)Nature CommunicationsSeptember 18, 201810.1038/s41467-018-06300-3Cited by 284SaveCiteExport RISWatch citationsRelated PapersHA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation|Blood|2024|29Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeutics|Journal for ImmunoTherapy of Cancer|2026|0